Stay updated with breaking news from Germany Based Immatics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Colin Kellaher Shares of Immatics moved higher in premarket trading Monday after the clinical-stage biopharmaceutical company formed a collaboration with...
By Colin Kellaher Shares of Immatics moved higher in premarket trading Monday after the clinical-stage biopharmaceutical company formed a collaboration with vaccine maker Moderna to develop...
Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
The firm also reported interim data from a Phase I trial of its T-cell receptor-based cell therapy in PRAME-expressing solid tumors.